ArticleMedicine2025
Assessing the concordance between centromere AC-3 immunofluorescence pattern and anti-centromere protein-B antibody, and analyzing clinical correlates of dual positivity: A retrospective study.
Article in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study evaluates the consistency between the centromere AC-3 immunofluorescence pattern and the anti-centromere protein B (anti-CENP-B) antibody test results and analyzes differences in the positive rates of potential related diseases with anti-centromere antibody (ACA) positivity. A retrospective collection of antinuclear antibody fluorescent patterns and anti-CENP-B test data from inpatients at Maanshan People's Hospital between February 2022 and February 2024 was performed. The consistency of different methods was evaluated using the kappa test and overall consistency calculation. Subsequently, the main diagnostic information of patients with ACA positivity was extracted, and the positive rates of ACAs in potential related diseases were analyzed. A total of 7893 patients were tested for both antinuclear antibody patterns and anti-CENP-B antibodies. Among them, 3959 patients were tested for ACAs using indirect immunofluorescence and Western blotting; 3936 patients were tested by indirect immunofluorescence and multiplex flow cytometric immunoassay. The consistency analysis showed that the kappa coefficients for both comparisons were >0.81, and the overall consistency was >99%, indicating that the AC-3 pattern and anti-CENP-B antibody test results were almost completely consistent. ACA positivity was observed in a variety of autoimmune diseases, with systemic sclerosis showing the highest positive rate (41.18%, 95% confidence interval: 32.12%-50.88%), followed by primary biliary cholangitis (40.00%, 95% confidence interval: 11.76%-76.93%). The positive rates of ACAs in 16 diseases were significantly higher than those in healthy control populations. There was almost complete consistency between the AC-3 pattern and the anti-CENP-B antibody test, suggesting that CENP-B is the main target antigen of the AC-3 pattern. ACA positivity was observed in various autoimmune diseases, especially systemic sclerosis and primary biliary cholangitis. This study offered useful insights for both basic and clinical investigations of ACAs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.